LEO Pharma A/S, a global leader in medical dermatology, is advancing the understanding of skin disease and its impact on patients’ lives with the presentation of 46 abstracts at the upcoming 2025 Fall Clinical Dermatology Conference taking place from Oct 23 – 26 in Las Vegas, Nevada. The data span multiple forms of skin disease, including chronic hand eczema (CHE), atopic dermatitis (AD), generalized pustular psoriasis (GPP) and pyoderma gangrenosum (PG).

“Fall Clinical Dermatology Conference is an important conference for researchers and clinicians specializing in dermatology, and we’re excited about the wealth of new data we will share at this meeting that can help advance dermatological care for those living with debilitating skin diseases,” said Shannon Schneider, Vice President of North America Medical Affairs for LEO Pharma. “Our deep commitment to advancing science and medicine is reflected in the large volume of new data, which spans a spectrum of dermatologic conditions and offers a more holistic perspective on the patient experience, real-world safety, efficacy, and the health economic impact of our treatments.”

Health Technology Insights: Brightwood Capital Provides Financing to Support Motor City Dental Partners’ Growth

Key data to be presented at the 2025 Fall Clinical Dermatology Conference by LEO Pharma include:

  • The first U.S. prevalence data on CHE, based on a survey of more than 10,000 people. The CHECK study includes findings on demographics, disease severity, healthcare resource utilization, and ability to work among CHE patients.1-5
  • New health economics and outcomes data that explores the burden of CHE in the U.S. and analyzes the potential financial impact of ANZUPGO® (delgocitinib) cream on a U.S. Commercial Health plan.7-10
  • Real-world ADBRY® (tralokinumab-ldrm) data, evaluating the safety and effectiveness of up to 12 months of treatment for patients with moderate to severe AD.21-27
  • New findings examining the burden of GPP in the U.S., as well as the effect of treatments such as SPEVIGO® (spesolimab).35-37

At the 2025 Fall Clinical Dermatology Conference, LEO Pharma will unveil its first data presentations on GPP and SPEVIGO since acquiring the product from Boehringer Ingelheim. SPEVIGO is now the third asset in LEO Pharma’s global portfolio.

About Chronic Hand Eczema

Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.47 HE is one of the most common skin disorders of the hands and in a substantial number of patients, it can develop into a chronic condition.48 CHE affects approximately one in ten adults worldwide.49,50 It is a fluctuating disease characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.47 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.49

CHE has been shown to cause psychological and functional burdens that impact patient quality of life,51,52 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities.53 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.

Health Technology Insights: LucyRx Acquires CerpassRx to Expand Prescription Care

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source- businesswire